Heartseed, Inc.
Heartseed, Inc. (219A.T) Stock Overview
Explore Heartseed, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
78.5B
P/E Ratio
-135.53
EPS (TTM)
$40.01
ROE
-0.10%
219A.T Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Heartseed, Inc. (219A.T) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 63.64, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $5399.53.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -135.53 and a market capitalization of 78.5B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
Heartseed, Inc. engages in the provision of cardiac regenerative medicine. The company was founded by Keiichi Fukuda, Takumi Akiyama, Toshiharu Furukawa and Yutaro Kasai on November 30, 2015 and is headquartered in Tokyo, Japan.
Keiichi Fukuda FACC,
39
5th Floor, Seavans South Building, Tokyo
2024